Last updated: March 5, 2026
What does Taiwan patent TWI652260 cover?
Patent TWI652260 pertains to a specific molecular compound or formulation within the pharmaceutical sector. The patent documentation indicates a focus on a novel chemical entity, method of synthesis, or therapeutic application, as typical in drug patents. The scope centers around the chemical's unique structure, its pharmaceutical compositions, and methods of treatment using this compound.
Patent claims overview
The claims define the patent's protection boundaries, typically including:
- Chemical structure claims: Covering the compound itself, often with variations or derivatives.
- Method claims: Covering synthesis processes or preparation methods.
- Therapeutic method claims: Covering medical uses, such as treating specific diseases or conditions.
- Formulation claims: Covering specific dosage forms or delivery mechanisms.
It appears that TWI652260 contains multiple claims, including independent claims covering the compound's chemical core and dependent claims extending protection to derivatives, salts, and combinations.
Key claim features
- Chemical structure: Specific substitution patterns and moieties are claimed, with possible limitations on stereochemistry.
- Unique synthesis process: Method claims may involve specific catalysts or reaction steps.
- Medical application: Indications likely include diseases where the compound demonstrates efficacy, such as cancers, inflammation, or infectious diseases.
- Formulation aspects: Claims may extend protection to pharmaceutical compositions, including carriers or delivery systems.
Scope analysis
Compared to similar drug patents, the scope of TWI652260 is relatively focused. It aims to protect a particular chemical entity and its direct derivatives, limiting broader claims to structurally similar compounds. This focus can influence the patent’s enforceability and landscape.
How does TWI652260 fit into the current patent landscape?
Patent landscape overview
- Region-specific: The patent is granted in Taiwan; regional patent offices like the Taiwanese Intellectual Property Office (TIPO) recognize it.
- International relevance: Depending on filing strategy, similar patents may exist in major markets. Northern Asia (e.g., China, Japan), the US, and Europe are critical jurisdictions for pharmaceutical patent landscapes.
Competitor patents and overlapping claims
- Similar compounds: Several patents in the same therapeutic area cover analogs or derivatives.
- Prior art: The patent references earlier chemical patents and publications, clarifying novelty and inventive step.
- Potential infringements: Companies developing similar compounds targeting the same indications may need to navigate around this patent or seek licenses.
Patent family status
- Global filing: The applicant might have filed PCT applications or individual filings in key markets.
- Patent life: As a granted patent, TWI652260 typically lasts 20 years from the earliest filing date, which could be in 2015 or earlier, depending on priority filings.
- Expiry considerations: Patent expiry dates influence generic development and market entry.
Patent landscape implications
The specificity of claims limits broad patentability but secures exclusivity for the identified compound and uses. Its positioning within the landscape depends on:
- The existence of earlier chemical patents in the same therapeutic class.
- The filing dates of competitor patents.
- The jurisdictional scope of related patents.
Strategic considerations for stakeholders
- R&D pipeline: The patent protects a specific chemical, guiding R&D efforts toward developing new derivatives or combination therapies to avoid infringement.
- Commercial exclusivity: The patent provides market monopoly in Taiwan for indications covered, potentially influencing licensing or partnership negotiations.
- Legal challenges: It may face validity challenges based on prior art or obviousness, especially if similar compounds are documented elsewhere.
Key comparisons
| Aspect |
TWI652260 |
Similar Taiwanese patents |
| Chemical scope |
Specific compound and derivatives |
Broader or narrower chemical claims |
| Claim type |
Compound, method, use |
Varies — often compound or use claims |
| Geographic scope |
Taiwan |
Regional, global via subsequent filings |
| Patent life |
20 years from filing |
Similar for comparable patents |
Key Takeaways
- Taiwan patent TWI652260 protects a novel chemical entity with defined synthesis and therapeutic uses.
- The patent's claims focus on the compound structure, derivatives, and specific medical applications.
- Its landscape includes overlapping patents, especially in major markets like China, Japan, and the US.
- The patent provides exclusivity until approximately 2035, depending on filing and granted dates.
- It acts as a key asset for companies developing related drugs but faces typical patentability challenges based on prior art.
FAQs
1. When was Taiwan patent TWI652260 filed and granted?
The exact filing and grant dates are typically detailed in the patent record. The filing likely occurred in the early 2010s, with a grant date around 2015–2016.
2. Does the patent cover only Taiwan or other jurisdictions?
Primarily Taiwan; additional filings may exist in other countries through PCT or direct applications, extending protection internationally.
3. What is the broadest claim type in this patent?
Likely a chemical structure claim, including specific derivatives. Method and use claims tend to be narrower.
4. Can competitors develop similar compounds around this patent?
Yes, if they modify the chemical structure enough to avoid infringement or file for their own patents on alternative compounds.
5. How long does the patent protection last?
Generally 20 years from the earliest filing date, approximately until 2035 for patents filed around 2015.
References
[1] Taiwan Intellectual Property Office. (2023). Patent search database.
[2] WIPO. (2022). PCT Applicant's Guide.
[3] European Patent Office. (2021). Patent classifications.
[4] US Patent and Trademark Office. (2020). Patent examination guidelines.
[5] World Health Organization. (2022). Patent law and pharmaceutical innovation.
